Hengrui Pharma(SH:600276) Ge Long Hui·2025-10-27 07:57Core Viewpoint - Heng Rui Medicine (1276.HK) experienced a significant increase of 5.21% to HKD 80.8 following the announcement of the approval for its innovative diabetes medication, marking a positive development for the company and the pharmaceutical sector in China [1] Company Summary - Heng Rui Medicine's subsidiary, Shandong Shengdi Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for its product, HR20031 tablets, which is the first domestically developed oral hypoglycemic combination drug in China [1] - The HR20031 tablets are designed to improve blood sugar control in adult patients with type 2 diabetes who have inadequate control with metformin hydrochloride [1] Industry Summary - According to a report from Galaxy Securities, the pharmaceutical sector has undergone a prolonged valuation adjustment but is now showing a significant structural recovery trend [1] - Public fund holdings in the pharmaceutical sector remain below historical averages, indicating potential for growth [1] - With supportive policies for commercial insurance development expected to improve payment conditions by 2025, innovative drugs and medical devices are likely to benefit [1] - The outlook for the pharmaceutical industry remains positive, with continued interest in innovative drug business development (BD) and a potential revival in pharmaceutical investment and financing [1]